Replies to post #24397 on Ayala Pharmaceuticals Inc (ADXS)

[exel_mm]

By another year, I'm thinking we shouldn't be surprised to see an early BO. I suspect that post EU approval, a buyout will quickly follow. The other, left-field scenario, is an early "cheap" BO just prior to EU submission, which is much less likely.

I hope that DOC does not settle for anything below 8B, but I my gut says the price will be around 4 or 5B, sometime in 2018 (or early 2019 if EU approval is late 2018 Q4).

Bottom-line, I don't think this company has 2 years of runaway as the entity "Advaxis". The platform is simply too compelling not to be gobbled up.

[shub]

Mastiffs;
"Not waiting another year"...Hah!

Do you see any massive, double blind , phase 3 clinical studies
testing our lead AXAL construct against a general cervical cancer population?

That's the one we have the best data and most solid clinical proof on and our best chance at FDA marketing approval. Right?

That would take another 3+ years, at least...Plus the FDA delays...plus...

And we haven't even started....And should have years ago when a ph 3 only cost $100.000 or so. We had the money then.